SCHEMBL5118834

SCHEMBL5118834

Cc1cccc(-c2nc3ccc(Cl)nn3c2-c2ccnc(N)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.47
MAPK13 O15264 6/20 0.45
MAPK12 P53778 6/20 0.45
MAPK11 Q15759 6/20 0.45
AKT1 P31749 1/20 0.43
AKT2 P31751 1/20 0.43
KHK P50053 1/20 0.42
DYRK3 O43781 2/20 0.40
CCNT1 O60563 2/20 0.40
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
CDK9 P50750 2/20 0.40
CDK5 Q00535 2/20 0.40
DYRK1A Q13627 2/20 0.40
CDK5R1 Q15078 2/20 0.40
DYRK2 Q92630 2/20 0.40
DYRK1B Q9Y463 2/20 0.40
RIPK3 Q9Y572 3/20 0.38
TGFBR1 P36897 2/20 0.38
PRMT5 O14744 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5126524 0.89 DYRK3 (0.48) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5116673 0.88 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5118524 0.84 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5127049 0.83 MAPK14 (0.42) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5114947 0.83 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5119333 0.83 MAPK14 (0.49) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL3106055 0.83 AKT1 (0.47) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5120116 0.82 MAPK13 (0.50) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL477098 0.81 PRMT5 (0.49) MAPK14MAPK13MAPK12MAPK11AKT1
SCHEMBL5126526 0.81 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK14 5/4885MAPK13 1/4885MAPK12 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.